STRABAG Property and Facility Services GmbH
Ergebnis der Suchanfrage nach (PF)
Newsrooms
Dienststellen
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
- 2
PM: KI-gestützte Computer Vision ist laut neuestem DHL Trend Report branchenprägende Technologie / PR: AI-driven computer vision has become an industry-shaping technology, finds latest DHL’s Trend Report
mehr Nichia Files Patent Infringement Lawsuit Against CoreStaff for Selling Bridgelux LEDs that Use KSF Phosphor Technology
Tokyo (ots) - On February 13, 2023, Nichia Corporation ("Nichia") filed a patent infringement lawsuit in the Tokyo District Court, seeking damages and to enjoin trading company CoreStaff Co., Ltd., from selling products from the F90 family of LEDs made by U.S.-based Bridgelux, Inc. The asserted patent in the ...
mehrEANS-News: European Lithium Limited / Secures Strategic Engagement Agreement with Talaxis - ATTACHMENT
http://resources.euroadhoc.com/documents/10207074/5/10482251/1/200527_EUR_Secures_Strategic_Engagement_Agreement_with_Talaxis.pdf issuer: European Lithium Limited Harrogate Street 32 AU-WA6007 West Leederville phone: +61 8 6181 9792 FAX: mail: ir@europeanlithium.com WWW: www.europeanlithium.com ISIN: AU000000EUR7 ...
mehrSysmex Inostics' SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM(TM) enhanced digital PCR technology for detection of mutations in circulating tumor DNA
Hamburg/Baltimore (ots) - Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics' novel ...
mehrSysmex Inostics OncoBEAM(TM) circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information ...
mehrSysmex Inostics' OncoBEAM(TM) platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived ...
mehrAutobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft
EANS-Capital Market Information: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft / New bond issues
issuer: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft Rotenturmstraße 5-9 PF 983 A-1010 Wien phone: +43 050108 - 10841 FAX: +43 050108 - 10842 mail: gabriele.csoklich@asfinag.at WWW: www.asfinag.at sector: Road Transport ISIN: - indexes: stockmarkets: stock market: Luxembourg Stock Exchange, ...
mehrAutobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft
EANS-Capital Market Information: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft / New bond issues
issuer: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft Rotenturmstraße 5-9 PF 983 A-1010 Wien phone: +43 050108 - 10841 FAX: +43 050108 - 10842 mail: gabriele.csoklich@asfinag.at WWW: www.asfinag.at sector: Road Transport ISIN: - indexes: stockmarkets: stock market: Luxembourg Stock Exchange, ...
mehrBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
mehrAutobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft
EANS-Capital Market Information: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft / New bond issues
issuer: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft Rotenturmstraße 5-9 PF 983 A-1010 Wien phone: +43 050108 - 10841 FAX: +43 050108 - 10842 mail: gabriele.csoklich@asfinag.at WWW: www.asfinag.at sector: Road Transport ISIN: - indexes: stockmarkets: stock market: Luxembourg Stock Exchange, ...
mehrAutobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft
EANS-Capital Market Information: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft / New bond issues
issuer: Autobahnen- und Schnellstraßen-Finanzierungs-Aktiengesellschaft Rotenturmstraße 5-9 PF 983 A-1010 Wien phone: +43 050108 - 10841 FAX: +43 050108 - 10842 mail: gabriele.csoklich@asfinag.at WWW: www.asfinag.at sector: Road Transport ISIN: - indexes: stockmarkets: stock market: Luxembourg Stock Exchange, ...
mehrEANS-News: AGENNIX AG Reports Additional Talactoferrin Alfa Data
company: AGENNIX AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 89 8565 2693 FAX: +49 89 8565 2610 mail: ir@agennix.com WWW: http://www.agennix.com sector: Pharmaceuticals ISIN: DE000A1A6XX4 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf, regulated dealing/prime standard: Frankfurt language: English ...
mehrFirst Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
Ingelheim, Germany, November 17 (ots/PRNewswire) - - Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First-in-Class Polo-Like Kinase 1 Inhibitor Soon to Enter Phase II - For non-US Healthcare Media Boehringer Ingelheim has marked a new ...
mehrData Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120)
Ingelheim, Germany (ots/PRNewswire) - - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename ...
mehr